• Title/Summary/Keyword: Ebola hemorrhagic fever

Search Result 3, Processing Time 0.022 seconds

Ebola Hemorrhagic Fever Outbreaks: Diagnosis for Effective Epidemic Disease Management and Control (에볼라 출혈열 발병 : 효과적인 전염병 관리 및 통제를 위한 진단)

  • Kang, Boram;Kim, Hyojin;Macoy, Donah Mary;Kim, Min Gab
    • Microbiology and Biotechnology Letters
    • /
    • v.45 no.2
    • /
    • pp.87-92
    • /
    • 2017
  • The first Ebola hemorrhagic fever outbreak occurred in the Democratic Republic of Congo and Sudan in 1976 and then emerged in West Africa in 2014 with a total of 27,741 cases and 11,284 deaths. The fever is caused by the Ebola virus, which belongs to the Filoviridae family and contains a ssRNA genome. The known subtypes of the virus are Bundibugyo ebolavirus, Reston ebolavirus, Sudan ebolavirus, $Ta\ddot{i}$ Forest ebolavirus, and Zaire ebolavirus. The Ebola outbreak was historically originated majorly from the East and Central African tropical belt. The current outbreaks in West Africa caused numerous deaths and spread fear in global society. In the absence of effective treatment strategies and any vaccine, accurate diagnosis is the most important contributing factor in the management and control of the epidemic disease. WHO (World Health Organization) has announced emergency guidance for the selection and use of Ebola in in vitro diagnostic assays. Numerous companies and research institutions have studied the various diagnosis methods and identified four WHO procurement approved as diagnosis kits: RealStar Ebolavirus Screen RT-PCR kit 1.0 (Altona), Liferiver-Ebola Virus (EBOV) Real time RT-PCR kit, Xpert Ebola Assay, and ReEBOV Antigen Rapid Test Kit. The efficiency of novel diagnostic kits such as Rapid Diagnosis Test (RDT) is currently being evaluated.

Systemic and oral manifestations of Ebola virus disease (에볼라 바이러스 감염의 전신 및 구강내 소견)

  • Kim, Min Ji;Kim, Hui Young;Kim, Soung Min;Myoung, Hoon;Lee, Jong Ho
    • The Journal of the Korean dental association
    • /
    • v.54 no.1
    • /
    • pp.67-83
    • /
    • 2016
  • Ebola virus disease is a lethal viral hemorrhagic fever that has been boiling in sub-Saharan Africa since 1970s. Last year, The Ebola virus epidemic that has spread not only mainly in West Africa, but also in locals such as USA, Europe and the Antipodes via infected travelers, was brought up. Human-to-human transmission of Ebola virus disease is known only through direct contact with the blood, secretions, tissues or other bodily fluids, including saliva. Although there has not been reported infection cases in the dental healthcare settings, the fact that the infection of the Ebola virus may be made from human secretions such as saliva suggests that there is a high risk of infection for the Ebola virus of dental healthcare workers. Therefore, it is important dental healthcare workers to identify infection-suspected patients through the oral findings for infection prevention. This article will review the oral signs and symptoms of Ebola virus disease and discuss the pathogenesis, treatment and prevention. Furthermore, Infection control guidelines for oral healthcare workers are also proposed.

  • PDF

The Strategic Plan for Preparedness and Response to Bioterrorism in Korea (우리나라의 생물테러 대비 및 대응방안)

  • Hwang, Hyun-Soon
    • Journal of Preventive Medicine and Public Health
    • /
    • v.41 no.4
    • /
    • pp.209-213
    • /
    • 2008
  • Following the Anthrax bioterrorism attacks in the US in 2001, the Korean government established comprehensive countermeasures against bioterrorism. These measures included the government assuming management of all infectious agents that cause diseases, including smallpox, anthrax, plaque, botulism, and the causative agents of viral hemorrhagic fevers (ebola fever, marburg fever, and lassa fever) for national security. In addition, the Korean government is reinforcing the ability to prepare and respond to bioterrorism. Some of the measures being implemented include revising the laws and guidelines that apply to the use of infectious agents, the construction and operation of dual surveillance systems for bioterrorism, stockpiling and managing products necessary to respond to an emergency (smallpox vaccine, antibiotics, etc.) and vigorously training emergency room staff and heath workers to ensure they can respond appropriately. In addition, the government's measures include improved public relations, building and maintaining international cooperation, and developing new vaccines and drugs for treatments of infectious agents used to create bioweapons.